François Corbin, Université de Sherbrooke

Research

Autism Spectrum Disorder Cannabidiol Fragile-X Syndrome Gaba Magnetic Resonance Spectroscopy Transcranial Magnetic Stimulation

Latest papers

Factors impacting the transition to adulthood of youth with fragile X syndrome and their families: Facilitators, obstacles and needs.
Research in developmental disabilities · 2020
Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).
Arteriosclerosis, thrombosis, and vascular biology · 2019
New insights of altered lipid profile in Fragile X Syndrome.
PloS one · 2017 · senior author

All 5 publications

Latest funding

Identification de biomarqueurs de réponse thérapeutique chez le syndrome du X fragile
CIHR · 2021 · Supervisor
$105,000
Targeting the endocannabinoid system to correct GABA abnormalities in patients with Fragile-X syndrome
CIHR · 2020 · Principal investigator
$531,675
Étude des profils de biomarqueurs plaquettaires chez des individus avec Syndrome du X fragile avant et après traitement à la lovastatine; relation avec la réponse cognitive.
CIHR · 2013 · Supervisor
$17,500

All 3 grants and awards

5 publications.

01

Factors impacting the transition to adulthood of youth with fragile X syndrome and their families: Facilitators, obstacles and needs.

Gauthier-Boudreault C, Gallagher F, Trépanier J, Corbin F, Couture M

Research in developmental disabilities2020

DOI: 10.1016/j.ridd.2020.103674 PMID: 32535492

02

Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).

Ben Djoudi Ouadda A, Gauthier MS, Susan-Resiga D, Girard E, Essalmani R, Black M, Marcinkiewicz J, Forget D, Hamelin J, Evagelidis A, Ly K, Day R, Galarneau L, Corbin F, Coulombe B, Çaku A, Tagliabracci VS, Seidah NG

Arteriosclerosis, thrombosis, and vascular biology2019

DOI: 10.1161/atvbaha.119.313247 PMID: 31553664

03

New insights of altered lipid profile in Fragile X Syndrome.

Çaku A, Seidah NG, Lortie A, Gagné N, Perron P, Dubé J, Corbin F

PloS one2017Senior author

DOI: 10.1371/journal.pone.0174301 PMID: 28334053

04

Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study.

Çaku A, Pellerin D, Bouvier P, Riou E, Corbin F

American journal of medical genetics. Part A2014Senior author

DOI: 10.1002/ajmg.a.36750 PMID: 25258112

05

Unusual subcellular confinement of the fragile X mental retardation protein (FMRP) in circulating human platelets: complete polyribosome dissociation.

Lauzière V, Lessard M, Meunier AJ, McCoy M, Bergeron LJ, Corbin F

Biochimie2012Senior author

DOI: 10.1016/j.biochi.2011.12.014 PMID: 22210492

Identification de biomarqueurs de réponse thérapeutique chez le syndrome du X fragile

SupervisorCIHR2021Doctoral Research Award: Canada Graduate Scholarships

Principal investigators: Dionne, Olivier

Keywords: Biochimie; Biologie Cellulaire Et Moléculaire; Cellules Souches Pluripotentes Induites; Déficience Intellectuelle; Microscopie Confocale; Protéomique; Recherche Translationelle; Syndrome Du X Fragile; Transcriptomique; Troubles Du Spectre Autistique

$105,000

Targeting the endocannabinoid system to correct GABA abnormalities in patients with Fragile-X syndrome

Principal investigatorCIHR2020Project Grant

Principal investigators: Lepage, Jean-Francois; Corbin, François

Keywords: Autism Spectrum Disorder; Cannabidiol; Fragile-X Syndrome; Gaba; Magnetic Resonance Spectroscopy; Transcranial Magnetic Stimulation

$531,675

Étude des profils de biomarqueurs plaquettaires chez des individus avec Syndrome du X fragile avant et après traitement à la lovastatine; relation avec la réponse cognitive.

SupervisorCIHR2013Master's Award: Canada Graduate Scholarships

Principal investigators: Pellerin, David

Keywords: Analyse Protéique; Analyse Quantitative; Biomarqueurs; Corrélation Phénotypique; Fmrp; Génétique Clinique; Modèles Plaquettaires; Syndrome Du X Fragile; Voies De Signalisation; Études Cliniques

$17,500

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Robert Day

Surgery

1 shared papers, latest 2019

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2020

Subject: Prospective PhD student: Autism Spectrum Disorder Dear Professor Corbin, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Factors impacting the transition to adulthood of youth with fragile X syndrome and their families: Facilitators, obstacles and needs." (2020), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Targeting the endocannabinoid system to correct GABA abnormalities in patients with Fragile-X syndrome" (2020), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]